Tom Melvin

Tom Melvin

Auto-generated profile, based on publicly available information

Tom Melvin

Institute for Clinical Trials, College of Medicine, Nursing and Health Sciences, University of Galway, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SGStephen Gilbert
Stephen Gilbert
HHHugh Harvey
Hugh Harvey
TMTom Melvin
Tom Melvin
EVErik Vollebregt
Erik Vollebregt
PWPaul Wicks
Paul Wicks

19 January 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HMHani Marcus
Hani Marcus
PRPedro T. Ramirez
Pedro T. Ramirez
DKDanyal Khan
Danyal Khan
HHHugo Layard Horsfall
Hugo Layard Horsfall
JHJohn G. Hanrahan
John G. Hanrahan
PMPeter McCulloch
Peter McCulloch
The next generation of surgical robotics is poised to disrupt healthcare systems worldwide, requiring new frameworks for evaluation. However, evaluation during a surgical robot’s development is challenging due to their complex evolving nature, potential for wider system disruption and integration with complementary technologies like artificial intelligence. Comparative clinical studies require attention to intervention context, learning curves and standardized outcomes. Long-term monitoring needs to transition toward collaborative, transparent and inclusive consortiums for real-world data collection. Here, the Idea, Development, Exploration, Assessment and Long-term monitoring (IDEAL) Robotics Colloquium proposes recommendations for evaluation during development, comparative study and clinical monitoring of surgical robots—providing practical recommendations for developers, clinicians, patients and healthcare systems. Multiple perspectives are considered, including economics, surgical training, human factors, ethics, patient perspectives and sustainability. Further work is needed on standardized metrics, health economic assessment models and global applicability of recommendations.

14 April 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SGStephen Gilbert
Stephen Gilbert
SAStuart Anderson
Stuart Anderson
MDMartin Daumer
Martin Daumer
PLPhoebe Li
Phoebe Li
TMTom Melvin
Tom Melvin
RWRobin Williams
Robin Williams
Artificial intelligence (AI) and machine learning medical tools have the potential to be transformative in care delivery; however, this change will only be realized if accompanied by effective governance that ensures patient safety and public trust. Recent digital health initiatives have called for tighter governance of digital health. A correct balance must be found between ensuring product safety and performance while also enabling the innovation needed to deliver better approaches for patients and affordable efficient health care for society. This requires innovative, fit-for-purpose approaches to regulation. Digital health technologies, particularly AI-based tools, pose specific challenges to the development and implementation of functional regulation. The approaches of regulatory science and “better regulation” have a critical role in developing and evaluating solutions to these problems and ensuring effective implementation. We describe the divergent approaches of the European Union and the United States in the implementation of new regulatory approaches in digital health, and we consider the United Kingdom as a third example, which is in a unique position of developing a new post-Brexit regulatory framework.

28 July 2022 in IEEE Journal of Translational Engineering in Health and Medicine
Verified
Journal Article
Open access
TMTom Melvin
Tom Melvin
The Medical Device Regulation (EU) 745/2017 (MDR) has replaced the medical device directives which were in place since the early 1990s. MDR introduces a number of changes of relevance to biomedical engineers who work in healthcare institutions or with medical devices. This includes changes relating to devices produced in healthcare institutions, custom-made devices, single use devices, devices without an intended medical purpose, clinical investigations and device traceability. There are also challenges in implementation of the MDR, with a shortage of available notified bodies needed to conduct conformity assessment, with a consequent risk of product unavailability. Understanding these changes is important as implementing new requirements in practice may require additional resources or the introduction of new processes or systems.

31 January 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
OSOlamide Sadare
Olamide Sadare
TMTom Melvin
Tom Melvin
HHHugh Harvey
Hugh Harvey
EVErik Vollebregt
Erik Vollebregt
SGStephen Gilbert
Stephen Gilbert
Mobile apps are the primary means by which consumers access digital health and wellness software, with delivery dominated by the ‘Apple App Store’ and the ‘Google Play Store’. Through these virtual storefronts Apple and Google act as the distributor (and sometimes, importer) of many thousands of health and wellness apps into the EU, some of which have a medical purpose. As a result of changes to EU law which came into effect in May 2021, they must now ensure that apps are compliant with medical devices regulation and to inform authorities of serious incidents arising from their use. The extent to which these new rules are being complied with in practice is uneven, and in some areas unclear. In light of EU legislation related to competition, which came into effect in November 2022, it is also unclear how conflicts of interest can be managed between Apple and Google’s roles as gateway duopoly importers and distributors whilst also developers of their own competitive health products. Finally, with the proposed European health data space regulation, wellness apps will be voluntarily registered and labelled in a fashion more like medical devices than consumer software. We explore the implications of these new regulations and propose future models that could resolve the apparent conflicts. All stakeholders would benefit from improved app store models to sustainably evolve safer, better, and fairer provision of digital health applications in the EU. As EU legislation comes into force it could serve as a template for other regions globally.

18 October 2022 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
MTMelvin T
Melvin T
KDKenny D
Kenny D
GMGewillig M
Gewillig M
FAFraser Ag
Fraser Ag